Tract-based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants

Brain

Volumn 138, Issue 2, 2015, Pages 388-397

  O'Gorman, Ruth L ^a   Bucher, Hans U ^b   Held, Ulrike ^b   Koller, Brigitte M ^b   Hüppi, Petra S ^b,c   Hagmann, Cornelia F ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Brain development; Neuroprotection; Oligodendrocyte; Tractography; White matter lesion

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN;

ARTICLE; BRAIN DEVELOPMENT; CAPSULA INTERNA; CHRONIC LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORPUS CALLOSUM; DIFFUSION TENSOR IMAGING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FRACTIONAL ANISOTROPY; GENDER; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NECROTIZING ENTEROCOLITIS; NEUROPROTECTION; PREMATURITY; PRIORITY JOURNAL; PYRAMIDAL TRACT; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STATISTICAL ANALYSIS; WHITE MATTER; CLINICAL TRIAL; DIFFUSION WEIGHTED IMAGING; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MULTICENTER STUDY; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; SEXUAL DEVELOPMENT;

DIFFUSION MAGNETIC RESONANCE IMAGING; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MAGNETIC RESONANCE IMAGING; MALE; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; PYRAMIDAL TRACTS; RECOMBINANT PROTEINS; SEX CHARACTERISTICS; WHITE MATTER;

EID: 84922341754     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu363     Document Type: Article

References (73)

1. Alexandrou G, Martensson G, Skiold B, Blennow M, Aden U, Vollmer B. White matter microstructure is influenced by extremely preterm birth and neonatal respiratory factors. Acta Paediatr 2014; 103: 48-56.
2. Andersson JL, Jenkinson M, Smith M. Non-linear registration, aka Spatial normalisation FMRIB technical report TR07JA2, 2007a. www.fmrib.ox.ac.uk/analysis/techrep
3. Anjari M, Srinivasan L, Allsop JM, Hajnal JV, Rutherford MA, Edwards AD, et al. Diffusion tensor imaging with tract-based spatial statistics reveals local white matter abnormalities in preterm infants. Neuroimage 2007; 35: 1021-7.
4. Arzoumanian Y, Mirmiran M, Barnes PD, Woolley K, Ariagno RL, Moseley ME, et al. Diffusion tensor brain imaging findings at termequivalent age may predict neurologic abnormalities in low birth weight preterm infants. AJNR Am J Neuroradiol 2003; 24: 1646-53.
5. Back SA, Han BH, Luo NL, Chricton CA, Xanthoudakis S, Tam J, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002; 22: 455-63.
6. Back SA, Luo NL, Mallinson RA, O'Malley JP, Wallen LD, Frei B, et al. Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol 2005; 58: 108-20.
7. Ball G, Boardman JP, Arichi T, Merchant N, Rueckert D, Edwards AD, et al. Testing the sensitivity of Tract-Based Spatial Statistics to simulated treatment effects in preterm neonates. PLoS One 2013; 8: e67706.
8. Ball G, Counsell SJ, Anjari M, Merchant N, Arichi T, Doria V, et al. An optimised tract-based spatial statistics protocol for neonates: applications to prematurity and chronic lung disease. Neuroimage 2010; 53: 94-102.
9. Bassi L, Chew A, Merchant N, Ball G, Ramenghi L, Boardman J, et al. Diffusion tensor imaging in preterm infants with punctate white matter lesions. Pediatr Res 2011; 69: 561-6.
10. Berman JI, Mukherjee P, Partridge SC, Miller SP, Ferriero DM, Barkovich AJ, et al. Quantitative diffusion tensor MRI fiber tractography of sensorimotor white matter development in premature infants. Neuroimage 2005; 27: 862-71.
11. Bonifacio SL, Glass HC, Chau V, Berman JI, Xu D, Brant R, et al. Extreme premature birth is not associated with impaired development of brain microstructure. J Pediatr 2010; 157: 726-32 e1.
12. Brothwood M, Wolke D, Gamsu H, Benson J, Cooper D. Prognosis of the very low birthweight baby in relation to gender. Arch Dis Child 1986; 61: 559-64.
13. Chatagner A, Van der Looij Y, Huppi P, Gruetter R, Sizonenko S. Neuroprotective effects of chronic erythropoietin treatment on neonatal rat following hypoxia-ischemia. Pediatric Academic Societies, Society for Pediatric Research 2011: Baltimore; 2010.
14. Cheong JL, Thompson DK, Wang HX, Hunt RW, Anderson PJ, Inder TE, et al. Abnormal white matter signal on MR imaging is related to abnormal tissue microstructure. AJNR Am J Neuroradiol 2009; 30: 623-8.
15. Counsell SJ, Allsop JM, Harrison MC, Larkman DJ, Kennea NL, Kapellou O, et al. Diffusion-weighted imaging of the brain in preterm infants with focal and diffuse white matter abnormality. Pediatrics 2003; 112 (1 Pt 1): 1-7.
16. Counsell SJ, Shen Y, Boardman JP, Larkman DJ, Kapellou O, Ward P, et al. Axial and radial diffusivity in preterm infants who have diffuse white matter changes on magnetic resonance imaging at termequivalent age. Pediatrics 2006; 117: 376-86.
17. Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 2001; 79: 228-35.
18. Dudink J, Lequin M, van Pul C, Buijs J, Conneman N, van Goudoever J, et al. Fractional anisotropy in white matter tracts of very-low-birth-weight infants. Pediatr Radiol 2007; 37: 1216-23.
19. Fauchere JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008; 122: 375-82.
20. Fauchere JC, Koller B, Tschopp A, Bucher HU, Group SENT. Safety of high-dose erythopoietin for neuroprotection in preterm infants archives of disease in childhood. fetal and neonatal edition 2012; 97 (Suppl 2): A16.
21. Genc K, Genc S, Baskin H, Semin I. Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res 2006; 55: 33-8.
22. Ghezzi P, Bernaudin M, Bianchi R, Blomgren K, Brines M, Campana W, et al. Erythropoietin: not just about erythropoiesis. Lancet 2010; 375: 2142.
23. Gonzalez FF, Abel R, Almli CR, Mu D, Wendland M, Ferriero DM. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev Neurosci 2009; 31: 403-11.
24. Gonzalez FF, Ferriero DM. Neuroprotection in the newborn infant. Clin Perinatol 2009; 36: 859-80, vii.
25. Gonzalez FF, Larpthaveesarp A, McQuillen P, Derugin N, Wendland M, Spadafora R, et al. Erythropoietin increases neurogenesis and oligodendrogliosis of subventricular zone precursor cells after neonatal stroke. Stroke 2013; 44: 753-8.
26. Haynes RL, Folkerth RD, Keefe RJ, Sung I, Swzeda LI, Rosenberg PA, et al. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol 2003; 62: 441-50.
27. Hintz SR, Kendrick DE, Vohr BR, Kenneth Poole W, Higgins RD. Gender differences in neurodevelopmental outcomes among extremely preterm, extremely-low-birthweight infants. Acta Paediatr 2006; 95: 1239-48.
28. Huppi PS, Dubois J. Diffusion tensor imaging of brain development. Semin Fetal Neonatal Med 2006; 11: 489-97.
29. Huppi PS, Inder TE. Magnetic resonance techniques in the evaluation of the perinatal brain: recent advances and future directions. Semin Neonatol 2001; 6: 195-210.
30. Huppi PS, Maier SE, Peled S, Zientara GP, Barnes PD, Jolesz FA, et al. Microstructural development of human newborn cerebral white matter assessed in vivo by diffusion tensor magnetic resonance imaging. Pediatr Res 1998; 44: 584-90.
31. Huppi PS, Murphy B, Maier SE, Zientara GP, Inder TE, Barnes PD, et al. Microstructural brain development after perinatal cerebral white matter injury assessed by diffusion tensor magnetic resonance imaging. Pediatrics 2001; 107: 455-60.
32. Iwai M, Stetler RA, Xing J, Hu X, Gao Y, Zhang W, et al. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke 2010; 41: 1032-7.
33. Juul S. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol 2004; 31: 129-42.
34. Juul S. Neuroprotective role of erythropoietin in neonates. J Matern Fetal Neonatal Med 2012; 25 (Suppl 4): 105-7.
35. Juul S, Felderhoff-Mueser U. Epo and other hematopoietic factors. Semin Fetal Neonatal Med 2007; 12: 250-8.
36. Juul SE, McPherson RJ, Bammler TK, Wilkerson J, Beyer RP, Farin FM. Recombinant erythropoietin is neuroprotective in a novel mouse oxidative injury model. Dev Neurosci 2008a; 30: 231-42.
37. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008b; 122: 383-91.
38. Keller M, Yang J, Griesmaier E, Gorna A, Sarkozy G, Urbanek M, et al. Erythropoietin is neuroprotective against NMDA-receptormediated excitotoxic brain injury in newborn mice. Neurobiol Dis 2006; 24: 357-66.
39. Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res 2007; 61: 451-5.
40. Latal B. Prediction of neurodevelopmental outcome after preterm birth. Pediatr Neurol 2009; 40: 413-9.
41. Lepomaki V, Matomaki J, Lapinleimu H, Lehtonen L, Haataja L, Komu M, et al. Effect of antenatal growth on brain white matter maturation in preterm infants at term using tract-based spatial statistics. Pediatr Radiol 2013; 43: 80-5.
42. Leuchter RH, Gui L, Poncet A, Hagmann C, Lodygensky GA, Martin E, et al. Association between early administration of highdose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA 2014; 312: 817-24.
43. Miller SP, Vigneron DB, Henry RG, Bohland MA, Ceppi-Cozzio C, Hoffman C, et al. Serial quantitative diffusion tensor MRI of the premature brain: development in newborns with and without injury. J Magn Reson Imaging 2002; 16: 621-32.
44. Mizuno K, Hida H, Masuda T, Nishino H, Togari H. Pretreatment with low doses of erythropoietin ameliorates brain damage in periventricular leukomalacia by targeting late oligodendrocyte progenitors: a rat model. Neonatology 2008; 94: 255-66.
45. Mukherjee P, Miller JH, Shimony JS, Philip JV, Nehra D, Snyder AZ, et al. Diffusion-tensor MR imaging of gray and white matter development during normal human brain maturation. AJNR Am J Neuroradiol 2002; 23: 1445-56.
46. Neubauer AP, Voss W, Wachtendorf M, Jungmann T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol 2010; 67: 657-66.
47. Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol 1999; 19 (6 Pt 1): 403-6.
48. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 2004; 114: 1287-91.
49. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; CD004863.
50. Partridge SC, Mukherjee P, Henry RG, Miller SP, Berman JI, Jin H, et al. Diffusion tensor imaging: serial quantitation of white matter tract maturity in premature newborns. Neuroimage 2004; 22: 1302-14.
51. Peacock JL, Marston L, Marlow N, Calvert SA, Greenough A. Neonatal and infant outcome in boys and girls born very prematurely. Pediatr Res 2012; 71: 305-10.
52. Porter EJ, Counsell SJ, Edwards AD, Allsop J, Azzopardi D. Tractbased spatial statistics of magnetic resonance images to assess disease and treatment effects in perinatal asphyxial encephalopathy. Pediatr Res 2010; 68: 205-9.
53. Robinson S, Li Q, Dechant A, Cohen ML. Neonatal loss of gammaaminobutyric acid pathway expression after human perinatal brain injury. J Neurosurg 2006; 104 (6 Suppl): 396-408.
54. Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging 1999; 18: 712-21.
55. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008; 371: 261-9.
56. Sakuma H, Nomura Y, Takeda K, Tagami T, Nakagawa T, Tamagawa Y, et al. Adult and neonatal human brain: diffusional anisotropy and myelination with diffusion-weighted MR imaging. Radiology 1991; 180: 229-33.
57. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733-43.
58. Skiold B, Horsch S, Hallberg B, Engstrom M, Nagy Z, Mosskin M, et al. White matter changes in extremely preterm infants, a population-based diffusion tensor imaging study. Acta Paediatr 2010; 99: 842-9.
59. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002; 17: 143-55.
60. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006; 31: 1487-505.
61. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23 (Suppl 1): S208-19.
62. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009; 44: 83-98.
63. Stevenson DK, Verter J, Fanaroff AA, Oh W, Ehrenkranz RA, Shankaran S, et al. Sex differences in outcomes of very low birthweight infants: the newborn male disadvantage. Arch Dis Child Fetal Neonatal Ed 2000; 83: F182-5.
64. Sugawa M, Sakurai Y, Ishikawa-Ieda Y, Suzuki H, Asou H. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res 2002; 44: 391-403.
65. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2013. http://www.R-project.org/.
66. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, et al. A critical role of erythropoietin receptor in neurogenesis and poststroke recovery. J Neurosci 2006; 26: 1269-74.
67. van de Looij Y, Chatagner A, Quairiaux C, Gruetter R, Huppi PS, Sizonenko SV. Multi-modal assessment of long-term erythropoietin treatment after neonatal hypoxic-ischemic injury in rat brain. PLoS One 2014; 9: e95643.
68. van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev 2008; 59: 22-33.
69. van Kooij BJ, de Vries LS, Ball G, van Haastert IC, Benders MJ, Groenendaal F, et al. Neonatal tract-based spatial statistics findings and outcome in preterm infants. AJNR Am J Neuroradiol 2012; 33: 188-94.
70. Volpe J. Neurology of the newborn. 5th edn. Philadelphia, PA: Saunders Elsevier; 2008.
71. Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol 2009; 8: 110-24.
72. Woodward LJ, Anderson PJ, Austin NC, Howard K, Inder TE. Neonatal MRI to predict neurodevelopmental outcomes in preterm infants. N Engl J Med 2006; 355: 685-94.
73. Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012; 130: 683-91